摘要
目的 探讨miRNA-25在非小细胞肺癌组织中的表达及其与临床病理因素和预后之间的关系.方法 用实时定量PCR检测60例非小细胞肺癌组织及其配对的癌旁组织中miRNA-25的相对表达水平,分析miRNA-25的表达与肺癌临床病理特征和预后的关系.结果 miRNA-25在肺癌及癌旁组织中表达的Ct值分别为28.35±1.78和31.60±3.28,其在肺癌组织中的相对表达量（2-△△Ct）为2.743,该结果表明miRNA-25在肺癌组织中的表达显著高于配对的癌旁组织（t=6.756,P＜0.05）.此外,miRNA-25在有淋巴结转移的肺癌组织中的相对表达量高于无淋巴结转移的肺癌组织（x2=13.436,P＜0.001）;miRNA-25在TNM分期Ⅲ～Ⅳ期肺癌组织中的相对表达量高于I～Ⅱ期（x2=12.245,P＜0.001）,而其表达与年龄、性别、吸烟史、肿瘤病理类型、大小、分化程度均无相关性（x2=0.012～2.143,P＞0.05）;生存曲线显示,miRNA-25相对高表达组生存时间较低表达组明显缩短（P＜0.001）.结论 miRNA-25在肺癌组织中高表达,其与肺癌的临床病理分期、淋巴结转移及预后密切相关,可能成为肺癌诊断、预后判断标志及治疗的新的靶标.
Objective To explore the expression of miRNA-25 in non-small cell lung cancer （NSCLC） and study its relationship with clinicopathologic features and prognosis of non-small cell lung cancer.Methods The expressions of miRNA-25 in 60 NSCLC tissues and matched adjacent cancerous tissues were tested by quantitative real-time PCR,and analysis its relationship with clinical pathology information.Results MiRNA-25 organizes in NSCLC and matched adjacent cancerous tissues of expression of Ct value respectively were 28.35±1.78 and 31.60±3.28.It organized medium opposite amount of expression （2 △△Ct） to 2.743 in the lung cancer and it expressed that the expres-sion of miRNA-25 in non-small cell lung cancer tissues was higher than that in matched adjacent cancerous tissues （t=-6.756,P＜0.05）.It was significantly higher in NSCLC tissues with lymph node metastases than those without lymph node metastases （x2 =13.436,P＜0.001）.It was significantly higher in eases of TNM stage Ⅲ ～ Ⅳ than in those of TNM stage Ⅰ～ Ⅱ （x2 =12.245,P＜0.001）,but its expression had no relativity with age,sex,smoke cigarette a pathologic type,size of history,tumor and divide degree （x2 =0.012～2.143,P＞0.05）.Kaplan-Meier survival estimate showed that the patients with high miRNA-25 expression had a shorter survival compared with the patients with low miRNA-25 expression （P＜0.001）.Conclusion MiRNA-25 showed high expression in lung cancer,and its high level expression is highly related with clinical stage,lymph node metastases of NSCLC.It might be a marker for the diagnosis and prognosis judgment of NSCLC and a promising target for therapy.
出处
《现代检验医学杂志》
CAS
2014年第4期9-12,共4页
Journal of Modern Laboratory Medicine
基金
陕西省自然科学基础研究计划项目（2012JM4009）资助.
